IFP Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-7
Closed -$189 – 5330
2026
Q2
$189 Buy
+7
New +$169 ﹤0.01% 4862
2025
Q4
– Sell
-5
Closed -$61 – 4974
2025
Q3
$61 Buy
+5
New +$69 ﹤0.01% 4626
2025
Q2
– Sell
-4
Closed -$49 – 4439
2025
Q1
$46 Hold
4
– – ﹤0.01% 4036
2024
Q4
$34 Buy
+4
New +$41 ﹤0.01% 4351

IFP Advisors's KALV Position: Q3 2026 in Review

IFP Advisors sold out of KalVista Pharmaceuticals (KALV) in Q3 2026, closing a stake of 7 shares — an estimated $189 sold.

IFP Advisors first reported a position in KALV in Q4 2024 and held it in 4 quarters. The position peaked at $189 in Q2 2026. 0 funds tracked by Wall St. Rank hold KALV as of Q3 2026.

  • IFP Advisors reported no remaining KalVista Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • IFP Advisors sold 7 KalVista Pharmaceuticals shares in Q3 2026, an estimated $189.
  • IFP Advisors first reported a position in KalVista Pharmaceuticals in Q4 2024 and held it in 4 quarters.
  • IFP Advisors's KalVista Pharmaceuticals position peaked at $189 in Q2 2026.
  • 0 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.